Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Merck increases price...

    Merck increases price of five drugs including Keytruda in November

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 1 Dec 2018 3:45 AM  |  Updated On 1 Dec 2018 3:45 AM


    NEW YORK: Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 per cent and 6 per cent, including its top-selling cancer treatment Keytruda.The list price increases are the first that the U.S. drugmaker has made since pledging in July that it would not raise the average net price of all of its medicines by more than the inflation rate.

    Merck raised the price of cancer immunotherapy Keytruda, which is forecast to bring in more than $7 billion in sales this year, by around 1.5 per cent.

    That follows a similar price increase for Keytruda earlier in the year, according to data from Rx Savings Solutions, which collects pricing data to help its customers save money on drugs.

    It also raised the price of its human papillomavirus (HPV) vaccine Gardasil, which protects against cancers related to the virus, by around 6 per cent. Analysts expect Gardasil will generate around $3 billion in sales for Merck this year.

    It also raised the list price on three other vaccines.

    "Merck remains committed to responsibly pricing our medicines," Merck spokeswoman Pamela Eisele said in a statement. "We will continue to evaluate our portfolio of products to look for opportunities to further reduce costs for patients and the health care system."

    Eisele said the average net price of Merck's drugs, including rebates and discounts, fell 1.9 per cent in the United States in 2017.

    The latest increases earlier this month predate a Nov. 16 announcement by rival Pfizer Inc that it would raise prices on 41 of its medicines in January.

    Many drugmakers, including Pfizer, Roche and Novartis, in July, pledged not to raise prices for the remainder of 2018. Pfizer, under pressure from U.S. President Donald Trump, reversed course at the time and decided not to take previously announced price increases on some prescription medicines.

    Merck in July announced the lowering of list prices of a handful of medicines, including a hepatitis C treatment with a very small market share and six other older drugs with minuscule sales.

    Also Read: Merck cancer drug Keytruda succeeds in late-stage trial

    cancercancer treatment Keytrudahepatitis Chuman papillomavirusimmunotherapyKeytrudaMerckMerck & Co. IncNovartisPamela Eiselerival Pfizer IncRocheU S drugmaker
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok